Scandion Oncology (Sweden) Insiders
| SCOL Stock | SEK 0.02 0 5.41% |
Scandion Oncology employs about 14 people. The company is managed by 6 executives with a total tenure of roughly 33 years, averaging almost 5.0 years of service per executive, having 2.33 employees per reported executive. Breaking down Scandion Oncology's management performance can provide insight into the firm performance.
| Annie Rasmussen Insider Chief Director |
| Morten Nissen Insider G Counsel |
Scandion |
Scandion Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (0.4236) % which means that it has lost $0.4236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7402) %, meaning that it generated substantial loss on money invested by shareholders. Scandion Oncology's management efficiency ratios could be used to measure how well Scandion Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Scandion Oncology Workforce Comparison
Scandion Oncology AS is currently regarded as top stock in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 248. Scandion Oncology holds roughly 14.0 in number of employees claiming about 6% of stocks in Biotechnology industry.
Scandion Oncology Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Scandion Oncology Price Series Summation is a cross summation of Scandion Oncology price series and its benchmark/peer.
Scandion Oncology Notable Stakeholders
A Scandion Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Scandion Oncology often face trade-offs trying to please all of them. Scandion Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Scandion Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Annie Rasmussen | Chief Director | Profile | |
| Morten Nissen | G Counsel | Profile | |
| Mads Kronborg | Head Communication | Profile | |
| Nils MD | Scientific CoFounder | Profile | |
| Johnny MS | CFO CEO | Profile | |
| Alfredo MD | Chief Officer | Profile |
About Scandion Oncology Management Performance
The success or failure of an entity such as Scandion Oncology often depends on how effective the management is. Scandion Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Scandion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Scandion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Scandion Oncology AS, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. The company was founded in 2017 and is based in Copenhagen, Denmark. Scandion Oncology operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people.
Please note, the imprecision that can be found in Scandion Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Scandion Oncology AS. Check Scandion Oncology's Beneish M Score to see the likelihood of Scandion Oncology's management manipulating its earnings.
Scandion Oncology Workforce Analysis
Traditionally, organizations such as Scandion Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Scandion Oncology within its industry.Scandion Oncology Manpower Efficiency
Return on Scandion Oncology Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.7M | |
| Net Loss Per Executive | 8.6M |
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.